Skip to content

Editors

Harry Cassin
Publisher and Editor

Andy Spalding
Senior Editor

Jessica Tillipman
Senior Editor

Bill Steinman
Senior Editor

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington
Contributing Editor

Julie DiMauro
Contributing Editor

Thomas Fox
Contributing Editor

Marc Alain Bohn
Contributing Editor

Bill Waite
Contributing Editor

Shruti J. Shah
Contributing Editor

Russell A. Stamets
Contributing Editor

Richard Bistrong
Contributing Editor

Eric Carlson
Contributing Editor

Can anyone navigate the India defense blacklist?

India’s emergence as the largest importer of weapons in the world has coincided with well-intentioned efforts to clean up a procurement process with a history of bribery problems.

However, a blacklist system to ban errant arms dealers has potentially weakened efforts to modernize India’s outdated military and done little to actually stem corruption.… Continue Reading

Siemens compliance officer retaliation suit dismissed

A federal lawsuit by the compliance officer for Siemens’ healthcare business in China who said he was fired for internally reporting FCPA violations was dismissed Monday. The U.S. District Court in New York said the anti-retaliation provisions of the Dodd-Frank Act don’t apply outside the United States.… Continue Reading

JP Morgan rap sheet is deep and wide

JP Morgan Chase reached a tentative deal with the DOJ this weekend to settle a slew of past transgressions for $13 billion.

No word yet if the FCPA investigation triggered by the bank’s targeted hiring of princelings in China and elsewhere will be included in the settlement.… Continue Reading

Fed faults Commerzbank foreign account controls

The U.S. Federal Reserve said last week it was requiring Commerzbank AG in Germany and its New York branch to improve compliance with federal and state anti-money laundering (AML) laws.

The Fed action didn’t involve allegations of corruption or specific charges.… Continue Reading

U.S., China enforcement crossfire creates new risks

At the beginning of this year, China’s president Xi Jinping promised to fight both “tigers” and “flies” — high-ranking and low-ranking corrupt officials — in his crackdown on corruption. Since then, the anti-graft campaign has led to the conviction of Bo Xilai and to the front-page investigations of foreign companies in the pharmaceutical and oil and gas sectors, among others.… Continue Reading

Job: Deputy Compliance Officer

Job Title:  Deputy Compliance Officer

Employer: Novartis Pharmaceuticals

Location: East Hanover, New Jersey

 

Description

The Deputy Compliance Officer (DCO) directly supports the VP, Ethics & Compliance (CCO/CCH) and leads assigned elements of oversight of the compliance program .… Continue Reading

China Corruption Blotter (October 18, 2013)

The former president of a traditional Chinese medicine hospital in Anhui’s Fengtai Country was sentenced to five years in prison for accepting bribes worth $14,238 from four pharmaceutical companies and a construction contractor to help them promote their drugs and to obtain construction contracts.… Continue Reading

The next big thing — PR meets compliance

Corporate compliance programs are no longer classified as “nice to have,” nor are they mere responses to allegations of wrongdoing. Some companies are going beyond mentioning how they have cleared their names with regulators after an investigation; they’re actively promoting the components of an effective strategy.… Continue Reading